Advanced glycation end products: A nephrologist's perspective

被引:249
作者
Raj, DSC
Choudhury, D
Welbourne, TC
Levi, M
机构
[1] Univ Texas, SW Med Ctr, Dallas, TX USA
[2] Vet Affairs Med Ctr, Dallas, TX USA
[3] Louisiana State Univ, Med Ctr, Dept Med, Shreveport, LA 71130 USA
关键词
advanced glycation end products (AGEs); diabetes; renal failure; dialysis; aging; aminoguanidine (AGN); oxidant stress;
D O I
10.1016/S0272-6386(00)70189-2
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Advanced glycation end products (AGEs) are a heterogeneous group of molecules that accumulate in plasma and tissues with advancing age, diabetes, and renal failure. There is emerging evidence that AGEs are potential uremic toxins and may have a role in the pathogenesis of vascular and renal complications associated with diabetes and aging. AGEs are formed when a carbonyl of a reducing sugar condenses with a reactive amino group in target protein. These toxic molecules interact with specific receptors and elicit pleiotropic responses. AGEs accelerate atherosclerosis through cross-linking of proteins, modification of matrix components, platelet aggregation, defective vascular relaxation, and abnormal lipoprotein metabolism. In vivo and in vitro studies indicate that AGEs have a vital role in the pathogenesis of diabetic nephropathy and the progression of renal failure. The complications of normal aging, such as loss of renal function, Alzheimer's disease, skin changes, and cataracts, may also be mediated by progressive glycation of long-lived proteins. AGEs accumulate in renal failure as a result of decreased excretion and increased generation resulting from oxidative and carbonyl stress of uremia. AGE modified beta(2)-microglobulin is the principal pathogenic component of dialysis-related amyloidosis in patients undergoing dialysis, Available dialytic modalities are not capable of normalizing AGE levels in patients with end-stage renal disease. A number of reports indicated that restoration of euglycemia with islet-cell transplantation normalized and prevented further glycosylation of proteins. Aminoguanidine (AGN), a nucleophilic compound, not only decreases the formation of AGEs but also inhibits their action. A number of studies have shown that treatment with AGN improves neuropathy and delays the onset of retinopathy and nephropathy. N-Phenacylthiazolium bromide is a prototype AGE cross-link breaker that reacts with and can cleave covalent AGE-derived protein cross-links. Thus, there is an exciting possibility that the complications of diabetes, uremia, and aging may be prevented with these novel agents. (C) 2000 by the National Kidney Foundation, Inc.
引用
收藏
页码:365 / 380
页数:16
相关论文
共 140 条
[1]  
ABEL M, 1995, NEPHROL DIAL TRANSPL, V10, P1662
[2]  
AHMED MU, 1988, J BIOL CHEM, V263, P8816
[3]  
AHMED MU, 1986, J BIOL CHEM, V261, P4889
[4]  
[Anonymous], KIDNEY INT
[5]  
ATESHKADI A, 1995, PERITON DIALYSIS INT, V15, P129
[6]  
Baylis C, 1996, SEMIN NEPHROL, V16, P265
[7]  
BAYNES JW, 1980, DIABETES, V29, P524
[8]   FORMATION OF IMMUNOCHEMICAL ADVANCED GLYCOSYLATION END-PRODUCTS PRECEDES AND CORRELATES WITH EARLY MANIFESTATIONS OF RENAL AND RETINAL DISEASE IN DIABETES [J].
BEISSWENGER, PJ ;
MAKITA, Z ;
CURPHEY, TJ ;
MOORE, LL ;
JEAN, S ;
BRINCKJOHNSEN, T ;
BUCALA, R ;
VLASSARA, H .
DIABETES, 1995, 44 (07) :824-829
[9]   Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus [J].
Berg, TJ ;
Bangstad, HJ ;
Torjesen, PA ;
Osterby, R ;
Bucala, R ;
Hanssen, KF .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1997, 46 (06) :661-665
[10]   Increased serum levels of advanced glycation end products (AGEs) in children and adolescents with IDDM [J].
Berg, TJ ;
DahlJorgensen, K ;
Torjesen, PA ;
Hanssen, KF .
DIABETES CARE, 1997, 20 (06) :1006-1008